Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
ConditionHidradenitis Suppurativa (HS)
Trial statusRecruiting
Trial phasePhase 3
Trial typeInterventional
Biological sexAll
Age18+
SponsorIncyte Corporation
About this trial
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
Eligibility criteria
Qualifiers
Ability to comprehend and willingness to sign a written ICF for the study.
Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or tolerability concerns, per investigator's assessment.
Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator.
Demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements.
Disqualifiers
Had been permanently discontinued from study treatment during the parent study.
Had temporary study drug interruption due to safety and/or efficacy reasons at or after the final visit of the parent study.
Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab).
Live, attenuated vaccine.
Trial design
Treatments tested in this trial
- povorcitinib
Treatment groups
600 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov